Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NYSERT vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Treatment of vulvovaginal candidiasis in adult and adolescent females (FDA-approved),Off-label: Treatment of mixed vaginal infections (bacterial vaginosis with candidiasis),Off-label: Prevention of recurrent vulvovaginal candidiasis
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
10 mg orally once daily at bedtime, with or without food.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life approximately 20-25 hours in healthy adults; prolonged in hepatic impairment (up to 40 hours) and in elderly patients.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Nystatin is not absorbed systemically; metabolized in the gut via unknown pathways, excreted unchanged in feces. Sertaconazole: Primarily hepatic metabolism via CYP3A4 to inactive metabolites; minimal systemic absorption (<1%).
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily hepatic metabolism (CYP3A4) followed by biliary excretion of metabolites; ~60% fecal, ~30% renal (as metabolites), <5% unchanged in urine.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~99% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd approximately 7-10 L/kg, indicating extensive tissue distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability is ~60% due to first-pass metabolism; not available parenterally.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min). Severe renal impairment (e GFR <30 m L/min) not studied; use with caution. No pharmacokinetic data for dialysis.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: not recommended due to lack of data.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not approved for pediatric patients (safety and efficacy not established).
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment recommended; monitor for adverse effects due to age-related decreased clearance. Starting dose of 5 mg may be considered for elderly patients with frailty or comorbidities.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Hypersensitivity reactions (urticaria, angioedema) possible; discontinue if irritation occurs; avoid intravaginal use in patients with known hypersensitivity to any azole or polyene antifungals; not for oral, ophthalmic, or systemic use; may weaken latex condoms and diaphragms (avoid use within 72 hours of product use); pregnancy category C (use only if clearly needed); breastfeeding women: use caution due to possible infant exposure.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Known hypersensitivity to nystatin, sertaconazole, or any component of the formulation; acute hepatic porphyria (sertaconazole component); concurrent use with terfenadine, astemizole, cisapride, or other CYP3A4 substrates with narrow therapeutic index (sertaconazole component).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No known food interactions with topical nystatin. For oral suspension, avoid food or drink for 30 minutes after administration to maximize contact time.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal abnormalities at high doses. Second and third trimesters: Risk of preterm labor, low birth weight, and neonatal adaptation syndrome (e.g., respiratory depression, jitteriness) with chronic use. Avoid use unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Excreted in breast milk; M/P ratio not established. Use with caution in breastfeeding, especially in neonates or preterm infants, due to potential sedation or respiratory depression. Monitor infant for drowsiness, poor feeding, and weight gain.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No standard dose adjustments; use lowest effective dose for shortest duration. Pharmacokinetics in pregnancy: increased clearance may require higher doses for analgesia; however, avoid long-term use due to fetal risks. For labor analgesia, typical doses apply with careful monitoring.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
NYSERT (nystatin) is a polyene antifungal used topically for Candida infections. Do not use for systemic fungal infections. Monitor for local irritation or sensitization. In oral thrush, ensure contact time by holding suspension in mouth before swallowing. For vaginal use, continue through menstruation. For diaper rash, combine with barrier cream and frequent diaper changes.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Use exactly as directed for the full duration, even if symptoms improve.,For oral suspension: swish in mouth for several minutes before swallowing; do not eat or drink for 30 minutes after.,For topical cream: apply thin layer to affected area; avoid contact with eyes.,For vaginal tablets: insert high into vagina at bedtime; use sanitary pad to protect clothing.,Stop use and consult doctor if rash, irritation, or allergic reaction occurs.,Keep out of reach of children; do not use if allergic to nystatin or any ingredient.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NYSERT vs ABSTRAL, answered by our medical review team.
NYSERT is a Antifungal that works by NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NYSERT and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NYSERT is: 10 mg orally once daily at bedtime, with or without food.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NYSERT and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NYSERT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal abnormalities at high doses. Second and third trimesters: Risk of preterm labor, low. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.